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Abstract: (1) Background: Andrographolide (AN), the main diterpenoid constituent of Andrographis
paniculata, has a wide spectrum of biological activities. The aim of this study was the development of
nanocochleates (NCs) loaded with AN and based on phosphatidylserine (PS) or phosphatidylcholine
(PC), cholesterol and calcium ions in order to overcome AN low water solubility, its instability under
alkaline conditions and its rapid metabolism in the intestine. (2) Methods: The AN-loaded NCs
(AN–NCs) were physically and chemically characterised. The in vitro gastrointestinal stability and
biocompatibility of AN–NCs in J77A.1macrophage and 3T3 fibroblasts cell lineswere also investigated.
Finally, the uptake of nanocarriers in macrophage cells was studied. (3) Results: AN–NCs obtained
from PC nanoliposomes were suitable nanocarriers in terms of size and homogeneity. They had an
extraordinary stability after lyophilisation without the use of lyoprotectants and after storage at room
temperature. The encapsulation e ciency was 71%, while approximately 95% of AN was released in
PBS after 24 h, with kinetics according to the Hixson–Crowell model. The in vitro gastrointestinal
stability and safety of NCs, both in macrophages and 3T3 fibroblasts, were also assessed. Additionally,
NCs had extraordinary uptake properties in macrophages. (4) Conclusions: NCs developed in this
study could be suitable for both AN oral and parental administration, amplifying its therapeutic value.
Keywords: soy lecithin liposomes; nanocochleates; andrographolide; freeze-drying; gastrointestinal
stability; uptake and safety
1. Introduction
The design and production of appropriate drug delivery systems, in particular, nanosized ones,
o↵er an advanced approach to optimised bioavailability and/or the stability of drugs, to control drug
delivery and to maintain drug stability during transport to the site of action. A successful drug carrier
system should possess a long shelf life, optimal drug loading and release properties, and exert a much
higher therapeutic e cacy as well as have low side e↵ects [1,2].
Phospholipids are the main amphiphilic components of the cell membrane and currently represent
the main constituents of nanovectors because they can self-assembly in aqueous milieu, generating
di↵erent supramolecular structures such as micelles and vesicles [1,3]. Typically, their variation in head
groups, aliphatic chains and alcohols leads to a wide variety of phospholipids, generally classified
as glycerophospholipids and sphingomyelins. The most common natural glycerophospholipids are
phosphatidylcholine (PC), phosphatidylinositol, phosphatidylserine (PS), phosphatidylglycerol and
phosphatidic acid, having diverse acyl moieties, principally myristoyl, palmitoyl, oleoyl and stearoyl.
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In particular, glycerophospholipids are the specific constituents of liposomes, which are widely
used as drug vectors because of their high biocompatibility, non-toxicity, complete biodegradability,
and non-immunogenic e↵ects after both systemic and non-systemic routes of administration [4].
Conversely, the therapeutic use of vesicles has some limitations, principally poor stability and
availability under the harsh conditions typically presented in the gastrointestinal tract [1,2,5,6]. A very
limited number of studies report on the use of cochleates as an alternative platform to vesicles
in order to overcome these limitations. Cochleates were first observed by Verkleij et al. [7] using
phosphatidylglycerol liposomes and later by Papahadjopoulos et al. [8], using phosphatidylserine
liposomes in the presence of divalent metal cations (Me2+), i.e., Ca2+, Ba2+, Fe2+, Mg2+ and Zn2+.
Cochleates can be produced as nano- and microstructures and they are extremely biocompatible,
with excellent stability due to their unique compact structure. They present an elongated shape
and a carpet roll-like morphology always accompanied by narrowly packed bilayers, through the
interaction with Me2+ as bridging agents between the bilayers (Figure 1). During this arrangement,
the close approach of bilayers is dependent on dehydration of the head group of the phospholipid.
They roll-up in order to minimise their interaction with water and, consequently, cochleates possess
little or no aqueous phase. The relevant di↵erences between cochleates and di↵erent liposomes,
i.e., small unilamellar vesicle (SUV), large unilamellar vesicle (LUV), multilamellar vesicle (MLV) and
multivesicle vesicle (MVV), are reported in Figure 1.
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Yet what remains very unclear is their mechanism of permeation throughout the biological 
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the loaded drug into the blood vessel [10]. There are two current hypotheses to explain the 
mechanism of permeation. According to the first assumption, the contact of the calcium-rich 
membrane of the cochleate with a cell can cause a perturbation and the reordering of the cell 
membrane. Subsequently, there is fusion between the outer layer of the cochleate and the cell 
membrane [10]. An alternative hypothesis for the delivery mechanism of cochleates is phagocytosis. 
In both cases, once within the interior of a cell, a low calcium concentration results in the opening of 
the cochleate crystal and the release of the entrapped drug [11–13]. 
Currently, cochleates represent difficult drug delivery systems for clinical use, principally due 
to the numerous difficulties in producing monodisperse systems because of a tendency to form stable 
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The bilayers in a cochleate are organised very precisely at a very close repeating distance of 54
Angstro [9] ith a ater-free interior, hich is a rigid, stable, rod-shaped structure. Due to this
unique structure, cochleates can be easily lyophilised to a free-flowing powder that can be incorporated
in capsules for oral administration or re-dispersed in water for parental administration. Yet what
remains very unclear is their mechanism of permeation throughout the biological membranes. It is
reported that after oral administration, cochleates cross the epithelium, delivering the loaded drug
into the blood vessel [10]. There are two current hypotheses to explain the mechanism of permeation.
According to the first assumption, the contact of the calcium-rich membrane of the cochleate with a
cell can cause a perturbation and the reordering of the cell membrane. Subsequently, there is fusion
between the outer layer of the cochleate and the cell membrane [10]. An alternative hypothesis for the
delivery mechanism of cochleates is phagocytosis. In both cases, once within the interior of a cell, a low
calcium concentration results in the opening of the cochleate crystal and the release of the entrapped
drug [11–13].
Currently, cochleates represent di cult drug delivery systems for clinical use, principally due to
the numerous di culties in producing monodisperse systems because of a tendency to for stable
and huge aggregates, which represent a serious drawback at the industrial level. Diverse patents and
publications have reported di↵erent strategies to overcome these limitations [11], in particular, the use
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of methylcellulose, casein, or albumin, but proteins may decrease stability and safety due to the change
of pharmacokinetic parameters. Methylcellulose is able only in part to disrupt the formed aggregates.
Other natural polysaccharides (including celluloses, gums, and starches) have been recommended as
inhibitors of the aggregation processes, but their e ciency still remains ambiguous [11,12]. In recent
times, the ability of citric acid to remove Ca2+ ions from the external surface of cochleates, leading to
the dispersion of the aggregates, has been investigated [13]. Furthermore, a recent approach compared
a novel microfluidics-based strategy with the conventional cochleate production methods; however,
the formation of aggregates was still present in the samples [14].
The aim of this study was the production of monodisperse and stable nanocochleates (NCs) using
two di↵erent phospholipids, PC and PS, loaded with a typical small hydrophobic natural product,
andrographolide (AN) from the Asiatic medicinal plant Andrographis paniculata. Besides the numerous
potential activities ranging from anti-inflammatory to neuroprotection, antidiabetic to anti-obesity
properties, and antitumor activity to hepatoprotective activity [15], AN has poor water solubility
(3.29 ± 0.73 µg at 25  C) [16], which deeply limits its biodistribution and localisation, resulting in
low bioavailability [17]. Additionally, AN is unstable in gastrointestinal media and has a very short
biological half-life (t1/2 = 1.33 h) after a single oral dose [18]. The stability of developed nanocochleates
after lyophilisation and in simulated gastrointestinal fluids was investigated. In addition, the possible
hazards and the cellular e↵ects of NCs were determined using J774a.1 murine macrophages and 3T3
fibroblasts. Lastly, studies on uptake using a confocal microscope were carried out in the macrophages
cell line.
2. Materials and Methods
2.1. Materials
The phospholipon 90G (soy phosphatidylcholine, PC) was sourced from the Italian agent AVG
srl (Milan, Italy) of Lipoid AG (Cologne, Germany). The dioleoyl phosphatidylserine (PS) was a
kind gift from Lipoid AG (Cologne, Germany). The following reagents were from Sigma-Aldrich
(Milan, Italy): pepsin from porcine gastric mucosa, bile salts, andrographolide (AN), fluorescein
isothiocyanate (FITC, purity   90%, HPLC), lipase from porcin pancreas, sodium hydroxide (NaOH),
calcium chloride (CaCl2), cholesterol, phosphate bu↵ered saline (PBS) bioperformance certified,
paraformaldehyde (PFA), Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS),
l-glutamine, penicillin–streptomycin solution, WST-8 kit, acetonitrile (HPLC grade), methanol (HPLC
grade), formic acid (analytical grade), hydrochloric acid (HCl) (analytical grade) and dichloromethane
(CH2Cl2). The water used was from the Milli-Qplus system from Millipore (Milford, CT, USA).
The phosphotungstic acid (PTA) was from Electron Microscopy Sciences (Hatfield, PA, USA).
The dialysis kit was from Spectrum Laboratories, Inc. (Breda, The Netherlands). The J774a.1 murine
macrophages and the 3T3 fibroblasts were purchased from the American Type Culture Collection
(ATCC® TIB-67™, Manassas, VA, USA). A LT-4000 reader fromLabtechwas used to read the absorbance
(Bergamo, Italy).
2.2. Preparation of PC- and PS-based Liposomes and NCs
The NCs were obtained from nano-sized liposomes (LPs), which were prepared according to
the film hydration method [19]. The liposomes were formulated as follows: the required amounts of
phospholipids (60 mg) and cholesterol (20 mg) were dissolved in a dichloromethane/methanol mixture
(20 mL of a mixture, 3:2 v/v). The obtained organic solution was evaporated under vacuum and the
lipid film was hydrated by the addition of PBS (10 mL) using a mechanical stirrer (RW20 digital, IKA,
Staufen im Breisgau, Germany) for 30 min in a water bath at a constant temperature of 37  C for PC and
60  C for PS. The resulting formulations were optimised by ultrasonication (3 min, two cycles of 90 s)
in an ice bath to prevent lipid degradation. Subsequently, a gentle centrifugation (1205⇥ g, 1 min) was
performed to remove possible metallic particles released during the ultrasonication. The NCs were
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prepared from the nanoliposomes according to the trapping method, described by Asprea et al. [20].
Briefly, a 0.1 M solution of CaCl2 was added drop-by-drop to the liposomal suspension under magnetic
stirring (150 rpm, room temperature) until the formulation appeared cloudy, indicating the formation
of NCs. The molar ratio between PC and CaCl2 was 1:1, while the molar ratio between PS and CaCl2
was 1:4.
2.3. Characterisation of Nanocarriers: Size, Polydispersity Index and ⇣-Potential
The Zsizer Nano series ZS90 (Malvern Instruments, Malvern, UK) outfitted with a JDS Uniphase
22 mW He-Ne laser operating at 632.8 nm, an optical fiber-based detector, a digital LV/LSE-5003
correlator and a temperature controller (Julabo water-bath) set at 25  C was used for Dynamic
Light Scattering (DLS) measurements, including for the particle size, polydispersity index (PdI) and
⇣-potential. The cumulant method was used to analyse time correlation functions, obtaining the mean
diameter of the nanocarriers (Z-average) and the size distribution using the ALV-60X0 software V.3.X
provided byMalvern. The size characterisation technique for the nanoparticles in suspension, based on
the measurement of their translational di↵usion coe cient, related to the length, L, of their major axis
is as
D =
kBT
3⇡⌘L
FD, (1)
where ⌘ represents the viscosity of the solvent, kB represents the Boltzmann constant and T represents
the sample temperature. FD is a geometrical coe cient depending on the shape, but not the size,
of the particles [21,22]. In particular, for NCs, the expressions of FD corresponding to these particle
shapes are
FD = log⇢ + 0.312 + 0.565/⇢   0.1/⇢2, (2)
⇣-potential values were obtained from the electrophoretic mobility, using the Henry correction
to Smoluchowski’s equation. The samples were diluted in distilled water and an average of three
measurements at the stationary level were taken. A Haake temperature controller kept the temperature
constant at 25  C.
2.4. Morphological and Size Characterisation by Transmission Electron Microscopy (TEM)
A transmission electron microscope (TEM, Jeol Jem 1010, Tokyo, Japan) was used to evaluate the
morphology, shape and dimensions of NCs. The NCs dispersion was diluted 10-fold and placed on
a carbon film-covered copper grid and stained with a phosphotungstic acid solution 1 g/100 mL in
sterile water, before the TEM analysis. The samples were dried for 1 min and then examined under
TEM and photographed at an accelerating voltage of 64 kV.
2.5. Stability Study of NCs after Lyophilisation
The lyophilisation process of NCs provides an extended storage period at room temperature and
can be carried out without the use of lyoprotectants because of the very lowwater content. The samples
were frozen by a freezer ( 23  C) overnight before lyophilisation. Then, the samples were moved to a
freeze-drier. The temperature was set to  23  C and the pressure was  1.0 bar. The drying time was
24 h. The pressure and the temperature remained unchanged during the process.
The stability of the lyophilised NCs was evaluated after reconstitution of the colloidal system to
the original volume with distilled water, using a vortex mixer at room temperature. The samples were
stored in sealed glass containers after being placed into a desiccator containing silica gel to absorb
water vapor. The samples were also protected from light. The stability of the lyophilised NCs was
assessed by checking the size, ⇣-potential, polydispersity and morphology every week for 2 months.
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2.6. Stability Study of NCs in Gastrointestinal Media
NCs could be used to protect the entrapped compound from the e↵ects of the gastrointestinal fluids.
Accordingly, NC formulations were tested for their stability using simulated gastrointestinal conditions.
Simulated gastric fluid (SGF) was used to investigate the gastric stability of NCs, as previously
reported [23,24]. Briefly, 5mL of NCs was suspended in 5mL of SGF (0.32% w/v pepsin, 2 g of sodium
chloride and 7mL HCl dissolved in 1 L water and pH adjusted to 1.8 using 1 M HCl) and incubated at
37  C under shaking at a speed of 100 strokes/min. After 2 h, the sample was collected. The size and
PdI were analysed by DLS, while the morphology of the colloidal systems was analysed by TEM.
The stability of the samples was also investigated in simulated intestinal fluid (SIF) containing an
intestinal enzyme complex (lipase 0.4 mg/mL, bile salts 0.7 mg/mL and pancreatin 0.5 mg/mL) and
750mM calcium chloride solution at 37  C, under shaking, with a speed of 100 strokes/min. The pH of
the mixture was adjusted to a value of 7.0 with NaOH 0.1 N. After 2 h, the sample was collected and its
physical and morphological properties were assessed by size and PDI analysis by DLS and TEM.
2.7. Preparation of Nanocarriers Based on AN and FITC
NCs were obtained from nanoliposomes (SUVs), which were prepared using the film hydration
method. The nanoliposomes were formulated as follows: phospholipids (60 mg), cholesterol (20 mg)
and AN (20 mg) or FITC (5 mg) were dissolved in dichloromethane/methanol mixture (20 mL of a
mixture 3:2 v/v). The obtained organic solution was evaporated under vacuum to obtain a lipid film,
which was hydrated by the addition of PBS (10 mL) using a mechanical stirrer (RW20 digital, IKA,
Staufen im Breisgau, Germany) for 30 min in a water bath at a constant temperature of 37  C for PC
and 60  C for PS. The resulting formulations were reduced in size using an ultrasonication probe for
3 min (two cycles of 90 s). During the sonication, the samples were kept in an ice bath to prevent lipid
degradation. After that, a gentle centrifugation (1205⇥ g, 1 min) was performed to remove possible
metallic particles released during the ultrasonication. The NCs were prepared by the trapping method,
according to Asprea et al. [20]. A 0.1 M solution of CaCl2 was added drop-by-drop to the liposomal
suspension under magnetic stirring (150 rpm, at room temperature) until the formulation became
cloudy, indicating the formation of NCs. The molar ratio between PC and CaCl2 was 1:1, while the
molar ratio between PS and CaCl2 was 1:4.
2.8. Determination of Encapsulation E ciency of AN–NCs by HPLC
After preparation of the NCs, free AN was removed by dialysis using bags with a pore size of
3.5–5 kD, and according to previous studies [25]. The dialysis bag was placed in 1 L of distilled water
at room temperature for 1 h under stirring. The physical mixture was used as a control to validate
the procedure. The AN-loaded content was quantified by HPLC–DAD analysis using a standard
sample of AN, after the treatment of NCs with methanol to destroy the cochleates. HPLC–DAD
analyses were performed with a HP 1200 Liquid Chromatograph (Agilent Technologies, Palo Alto, CA,
USA), equipped with a Diode Array Detector (DAD), managed by a HP 9000 workstation (Agilent
Technologies). The column was a Varian Polaris RP18 (250 mm ⇥ 4.6 mm i.d., particle size 5 µm)
(Agilent Technologies) maintained at 27  C. The chromatograms were acquired at 223 nm. The eluents
were acetonitrile (A) and formic acid/water at pH 3.2 (B) at a flow rate of 1 mL/min. The following
gradient profile was applied: 0–3min, 10%A, and 90% B; 3–11min, 10–38%A, and 90–62% B; 11–25min,
38% A, and 62% B; 25–30 min, 38–50% A, and 62–50% B; and 30–34 min, 50–10% A, and 50–90% B.
The post time was 10 min. The injected volume of the samples was 10–20 µL.
The calibration curve was obtained from a dilution series of the AN reference standard solubilised
in MeOH, in the range between 56 and 0.56 ng/mL. Linear regression was used to establish the
calibration curve. AN was quantified using the peak areas acquired at 223 nm. The correlation
coe cient (R2) was 0.9995. The data are expressed as the mean ± SD of the three experiments.
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The encapsulation e ciency (EE%) for each preparation was calculated using the following
equation:
EE% = (Wt/Wi) ⇥ 100%, (3)
where Wt is the total amount of the loaded AN and Wi is the total quantity of AN added initially
during the preparation. The encapsulation e ciency was determined in triplicate.
2.9. Determination of Encapsulation E ciency of FITC–NCs by HPLC
Free FITC was removed by means of dialysis, as previously described. The contents of FITC
were determined by the same HPLC instrument used for AN quantification. The column was a
Lichrosorb RP18 (4.6 mm ⇥ 100 mm i.d., 5 µm) (Agilent Technologies) maintained at 27  C. The mobile
phases were (A) acetonitrile and (B) formic acid/water pH 3.2, at a flow rate of 0.8 mL/min and an
injection volume of 10 µL. The following gradient profile was used: 0–5 min, 10–40% A, and 90–60% B;
5–10 min, 40–50% A, and 60–50% B; 10–12 min 50–55% A, and 50–45% B; 12–15 min, 55% A, and 45% B;
15–18 min, 55–90% A, and 45–10% B; and 18–20 min, 10% A, and 90% B. The post time was 5 min.
The chromatograms were acquired at 224 nm. The linearity range of responses of FITC dissolved in
CH3OHwas determined on five concentration levels from 6.40 ng/mL to 520 ng/mL and the correlation
coe cient (R2) was 0.9994 [26].
The encapsulation e ciencywas calculatedusing the equationdescribed in the previous paragraph.
In this case, Wt is the total amount of the loaded FITC and Wi is the total quantity of FITC added
initially during the preparation.
2.10. In Vitro Release Study
The in vitro release of AN from the NCs was investigated using the dialysis bag method. In order
to simulate the physiological conditions, PBS (pH 7.4) and enzyme-free SGF and SIF were used as
dissolution media. A total of 2 mL of AN–NCs suspension was deposited into the dialysis membrane
(pore size 3.5 kD) and placed in 200 mL of the release medium. The temperature was set at 37  C and
the system was stirred at 150 rpm. Release into the PBS was monitored for 24 h while in SGF and for
2 h while in SIF, corresponding to the theoretical transit through the gastrointestinal tract; aliquots of
one millilitre were withdrawn in duplicate and replaced with fresh dissolution medium. The samples
were analysed by HPLC for the quantification of released AN. The percentage of AN released was
calculated as follows:
%AN released =
✓ ANr
ANtot
◆
⇥ 100, (4)
where ANr is the amount of AN detected by HPLC analyses and ANtot is the total quantity of AN
deposited into the dialysis membrane.
Furthermore, to evaluate the kinetics of drug release from the NCs, di↵erent mathematical models
were used, i.e., zero order and first order kinetics model, the Higuchi model, the Korsmeyer–Peppas
model and the Hixson–Crowell model. The best fitting model was selected according to the best
regression coe cient (R2) value for the release data.
2.11. Cell Viability and Uptake Studies
The albino mouse embryonic 3T3 fibroblast cell line and the murine monocyte/macrophage cell
line J774a.1 were used for cell viability and uptake studies [27,28]. The cell lines were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich) supplemented with foetal bovine
serum, 100 units/mL penicillin, and 100 µg/mL streptomycin; for the 3T3 cell line, an additional glucose
concentration (4.5 g/L) was used. The cells were maintained under standard culture conditions (37  C,
5% CO2, 95% air and 100% relative humidity).
The cells were inoculated into 96-well microplates and maintained under standard culture
conditions for 24 h to test the cell viability. Thereafter, the medium was replaced with fresh medium
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containing di↵erent concentrations of NCs or LPs. After 24 h, a WST-8 test was performed following
the kit protocol as indicated by the manufacturer and as described in [28]. Briefly, 100 µL of DMEM
supplemented with 10% WST-8 reagent was incubated in each well for 2 h at 37  C. The formazan
concentration was quantified by an optical absorbance at 450 nm, with a reference wavelength of
630 nm and by subtracting blank values. The data were expressed as a percentage of the optical
absorbance with respect to the controls.
The cells were inoculated into a 33-mm petri dish and maintained under standard culture
conditions for 24 h for uptake experiments. Subsequently, the medium was replaced with fresh
medium containing di↵erent concentrations of FITC loaded in NCs or SUVs. After 1 h, the medium
was removed and the cells were fixed in 3.6% PFA in PBS for 10 min at room temperature, stained with
DAPI and analysed by confocal imaging. Images were acquired by a Leica SP7 confocal microscope
and underwent no subsequent manipulation. A minimum of five di↵erent fields was acquired from
each sample and all samples were performed in triplicate.
3. Results
3.1. Preparation and Characterisation of NCs
The NCs were prepared according to the multi-step preparation reported in Figure 2.
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Figure 2. Multi-step preparation process of nanocochleates.
Briefly, as a first step, nanosized LPs were prepared according to the film hydration method using
PC or PS and cholesterol, in the gravimetric ratio reported in the experimental part. The lipid film was
dispersed in PBS to obtain MLVs. The formation of the SUVs was performed using an ultrasonication
probe. In a further step, the SUVs collapsed after the addition of CaCl2 solution when added in the
molar ratio 1:1 to PC liposomes (PC–SUVs) and in the molar ratio 4:1 to PS liposomes (PS–SUVs).
Then, the collapsed vesicles fused giving large sheets, which rolled-up to give NCs. The calcium ions
were essential for the stability of the system, and the aqueous phase in the structure of NCs was very
limited, as reported in Figure 2. Both the SUV and NC formulations were characterised in terms of
size, homogeneity and ⇣-potential by dynamic and electrophoretic light scattering (Table 1).
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Table 1. Physical characterisation of empty liposomes and nanocochleates.
Sample Size (nm) PdI ⇣-Potential (mV)
PC–SUVs 150 ± 2 0.20 ± 0.02  29.3 ± 0.9
PC–NCs 150 ± 2 0.24 ± 0.01  21.6 ± 1.3
PS–SUVs 205 ± 37 0.25 ± 0.03  37.2 ± 7.1
PS–NCs 207 ± 44 0.55 ± 0.05  36.4 ± 1.4
PC–SUVs: liposomes made of phosphatidylcholine; PC–NCs: nanocochleates made of phosphatidylcholine;
PS–SUVs: liposomes made of phosphatidylserine; PS–NCs nanocochleates made of phosphatidylserine. The data
are displayed as the mean ± SD; n = 3.
Both PC–SUVs and PC–NCs had a narrow size of ca. 150 nm and they were highly homogeneous
as evinced by the PdI (Table 1). Both the liposomes and the NCs based on PC were smaller than
those prepared with PS. In particular, the PS–NCs were not homogeneous (Table 1). The dimension
of the nanocarriers in the suspension was based on the measurement of their translational di↵usion
coe cient. This value is related to the length, L, of their major axis as described by Equation (1).
The shape of the particles, but not the size, is linked by the geometrical coe cient, FD, which is 1 for
spheres. However, it was determined for the NCs using a simplified geometry of long rods, according
to Equation (2) [19,20]. All the nanovectors were negatively charged, and, as expected, the ⇣-potential
was a very low for the nanocarriers based on PS.
The morphological characterisation was completed by the observation of TEM pictures. The size
and homogeneity of the liposomes based on PC and PS were confirmed (data not reported).
The cigar-like shape of PC–NCs was strongly assessed (Figure 3a). PC–NCs dimensions were
comparable with the dimensional distribution results obtained from the DLS analysis. The TEM images
of PS–NCs confirmed the presence of polydisperse systems with structures di↵erent to NCs (Figure 3b).
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phosphatidylserine. The data are displayed as the mean ± SD; n = 3. 
TEM analyses confirmed the dimensional data obtained by DLS concerning PC–NCs (Figure 4). 
Instantly after the preparation, PC–NCs had a dimension of 150 nm, while in the following 60 days 
their size increased by about 20 nm, while their ζ-potential values remained almost constant during 
this stability study. By contrast, the PS–NCs were not stable and their size increased by about 80 nm 
during storage. The TEM pictures showed the presence of aggregates (data not reported), confirming 
the results reported in Table 2. 
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3.2. Stability Study of Empty NCs
Firstly, the stability of the NCs was assessed by measuring the changes in terms of the average
dimensions, polydispersity and ⇣-potential values after the lyophilisation process and resuspension at
room temperaturewith distilledwater. The analysiswas performed immediately after the lyophilisation
process, which did not a↵ect the physical characteristics, when re-suspended in water, as reported in
Table 2. All the samples were reconstituted and analysed by DLS, ELS and TEM every week. It was only
the PC–NCs that did not experience considerable modification in size, homogeneity and ⇣-potential
values (Table 2).
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Table 2. The particle size, polydispersity index (PdI) and ⇣-potential of PC–NCs and PS–NCs as a
lyophilised product after two-month storage at 25  C.
PC–NCs t0 After 30 Days After 60 Days
Size (nm) 150 ± 2 166 ± 5 172 ± 3
PdI 0.24 ± 0.01 0.25 ± 0.02 0.25 ± 0.01
⇣-Potential (mV)  21.6 ± 1.3  19.4 ± 1.1  18.5 ± 1.0
PS–NCs t0 After 30 days After 60 days
Size (nm) 207 ± 44 292 ± 22 280 ± 25
PdI 0.55 ± 0.05 0.53 ± 0.04 0.55 ± 0.05
⇣-Potential (mV)  36.4 ± 1.4  31.4 ± 2.1  27.2 ± 1.1
PC–NCs: nanocochleates made of phosphatidylcholine; PS–NCs nanocochleates made of phosphatidylserine.
The data are displayed as the mean ± SD; n = 3.
TEM analyses confirmed the dimensional data obtained by DLS concerning PC–NCs (Figure 4).
Instantly after the preparation, PC–NCs had a dimension of 150 nm, while in the following 60 days
their size increased by about 20 nm, while their ⇣-potential values remained almost constant during
this stability study. By contrast, the PS–NCs were not stable and their size increased by about 80 nm
during storage. The TEM pictures showed the presence of aggregates (data not reported), confirming
the results reported in Table 2.
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Table 3. Physical and chemical characterisation of AN- and FITC-loaded LPs and NCs.
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The dimensions of the AN–NCs was ca. 150 nm, with a very low PdI, which resulted in suitability
for all routes of administration, not only oral [29]. These data were also reflected by the TEM which
exhibited NCs as tubular rod structures (Figure 5). The structure of the NCs is not modified in terms of
size by AN loading, which means that AN does not interfere with the cohesion and packing of the
apolar chains of the cochleate membrane. This is typical of small terpenes, which are able to decrease
the size of lipid nanocarriers by forcing the PC structure to increase its surface curvature [30].
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The average A -entrapment  ciency in both SUVs and NCs was obtained by HPLC–DAD;
the results were 71.1 ± 2.3 and 70.6 ± 5.9%, respectively (Table 3).
3.4. Stability of AN–NCs in Gastrointestinal Fluids
It is known that AN is not stable in the presence of gastrointestinal enzymes. Accordingly, one of
the aims of this study was the development of a formulation able to protect the incorporated compound
from degradation in gastrointestinal fluids. The gastrointestinal fluids may have an influence on the
integrity of NCs. The physical stability of AN–NCs was assessed in SGF (pH 2) and in SIF (pH 7).
These media did not a↵ect their structure after two hours of incubation. The DLS analyses revealed
that the mean diameter of the NCs was not a↵ected by these conditions: after incubation in both
gastro-enteric media, their mean size was 143 ± 1 nm with PdI 0.25 ± 0.02.
3.5. In Vitro Release Studies
After demonstrating the physical stability of NCs in gastrointestinal conditions, the in vitro release
of AN from NCs was investigated by the dialysis bag di↵usion technique. The test was carried out in
both SGF (pH 2) and SIF (pH 7) for two hours and in physiological pH conditions (PBS, pH 7.4) for 24 h.
The percentage of AN released in SGF was only 2.31 ± 0.02%, while in SIF, it was 14.75 ± 1.14%.
These results suggest that NCs may prevent AN burst release in the gastrointestinal tract, since about
85% of the compound remained entrapped in the NCs.
In PBS, the release of AN from NCs was not immediate, but gradual, unlike in the case of free-AN,
indicating that the formulation results in a more prolonged e↵ect (Figure 6).
The AN release from NCs can be described as a biphasic process and the mathematical model
of the drug release data was found to best fit the Hixson–Crowell release model: W
1
3
0  W
1
3
t = Kst;
whereW0 is the initial amount of the drug in the pharmaceutical dosage form;Wt is the remaining
amount of the drug in the pharmaceutical dosage form, at time t; and Ks is a constant, incorporating
the surface–volume relation. The R2 was 0.9961. This model has been frequently used to describe drug
release from several dosage forms with modified release. According to this model, the drug release is
described by dissolution, characterised by the surface area and diameter of the particles. Consequently,
based on the obtained results, it is possible to hypothesise that this behaviour may be due to the strong
a nity of hydrophobic AN to the lipid structure of NCs.
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3.6. Biocompatibility Studies
The biocompatibility of NCs was tested using two cell lines: macrophage J774a.1 and fibroblasts
3T3. SUVs were used as comparable reference nanovesicles. As a colorimetric, non-radioactive
assay, the WST-8 test was selected for assessing cell viability and proliferation because it indicates the
mitochondrial activity and hence reflects the cell viability. WST-8, a highly water-soluble tetrazolium
salt, is reduced to a soluble purple formazan derivative by trans-plasma membrane electron transport
from NADH via an electron mediator. The concentration of formazan was quantified by optical
absorbance at 450 nm,with a referencewavelength of 630 nmand by subtracting blank values. Themean
value and the standard deviation are the results of nine measurements: the test was performed in
three independent experiments and in each experiment, the samples were tested in triplicate. The data
were expressed as the percent of optical absorbance with respect to the controls. As indicated in
Figure 7, both SUVs and NCs showed no cytotoxicity at the concentration needed for massive uptake,
namely, with a dilution of 1:40. Higher concentrations showed a decrease in cell vi bility, validating
the dose–response curve. By contrast, it is remarkable that lower concentratio s of the nanovesicles
increased the cell metabolism rates, which was probably due to the active uptake process.
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Figure 7. Cell viability after 24 h of exposition to NCs or LPs. The concentrations are expressed in 
mg/mL. The data represent the percentage of control ± SD. The J774a.1 (a) is a 
monocytes/macrophages cell line; the 3T3 (b) is a fibroblasts cell line. 
3.7. Cellular Uptake Studies 
In Figure 8, the uptake of both NCs and SUVs by macrophage J774a.1 cell line, using 
nanoparticles loaded with FITC (FITC–NCs and FITC–SUVs), is reported. The uptake was tracked by 
the green fluorescence of FITC using a confocal microscope (Figure 8). 
 
Figure 8. Confocal images of the macrophage uptake of NCs (a) and SUVs (c). Following nuclear 
staining with DAPI and FITC encapsulation into NCs and SUVs, the cell nuclei appear in blue and 
the NCs/SUVs appear in green. The confocal images are also superimposed to Bright Field acquisition 
(b,d for NCs and SUVs, respectively) to show the unaltered morphology of the cells and the 
localisation of intracellular nanocarriers. 
Figure 7. Cel viability after 24 h of exposition to NCs or LPs. The concentrations are expres ed in
mg/mL. The data represent the percentage of control ± SD. The J774a.1 (a) is a monocytes/macrophages
cell line; he 3T3 (b) is a fibroblasts cell line.
3.7. Cellular Uptake Studies
In Figure 8, the uptake of both NCs and SUVs by macrophage J774a.1 cell line, using nanoparticles
loaded with FITC (FITC–NCs and FITC–SUVs), is reported. The uptake was tracked by the green
fluorescence of FITC using a confocal microscope (Figure 8).
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As reported in Figure 8, massive uptake takes place but the fluorescence is typically in the
cytoplasm without entering the cell nuclei. NCs and SUVs exhibit very similar uptake capability.
4. Discussion
In the present study, the potential of NCs is explored for the delivery of AN, a very promising active
natural constituent with various potential therapeutic benefits, but due to the low bioavailability and
instability in gastrointestinal media when administered with conventional dosage forms, it has never
reached a milestone therapeutic potential. Accordingly, the development of suitable delivery systems
for AN represents an urgent issue to formulate e↵ective therapeutic approaches. Lipid-based delivery
systems, especially vesicles, have attracted huge e↵orts as high bio-compatible and biodegradable
nanocarriers crossing membrane delivery systems because of their resemblance to the cell membrane.
One of the main drawbacks of conventional liposomes for oral administration is their poor stability in
the gastrointestinal environment. By contrast, NCs can easily be lyophilised to obtain solid, stable,
biocompatible and biodegradable nanovectors [1,2,5,6].
The NCs were simply developed from nanoliposomes (Figure 2), selecting both PS and PC
and cholesterol as lipid phases due to their close resemblance to natural membranes and their high
compatibility for human use. Ca2+ was selected among the diverse divalent cations to generate
NCs because it can enhance membrane fusion and phagocytosis. It is well documented that calcium
ions induce perturbations of the contact region and thereby promote the membrane fusion [11,31].
Astonishingly, in our studies, only PC and cholesterol generated monodisperse NCs with a tightly
packed structure after the addition of Ca2+. As previously reported, PS-based NCs are not stable,
producing systems with elevated polydispersity because of a tendency to form stable and huge
aggregates, which represents a serious drawback at the industrial level [15]. By contrast, developed
PC-based NCs were stable after lyophilisation and re-suspension in distilled water, and after incubation
in simulated gastric and intestinal media. In vitro dissolution studies explained an extended release,
making AN available over a prolonged period after administration. The PC-based NCs were
Pharmaceutics 2019, 11, 34 13 of 15
biocompatible. Even at high concentrations, the cell morphology and vitality were not a↵ected by
internalisation. Moreover, high cellular uptake of PC-based NCs was found in macrophages using
fluorescent nanovectors. After treatment of the cells with NCs, a bright fluorescent color of the
cytoplasm arose due to the FITC and it was clearly distinguished from the nucleus stained with DAPI.
Due to the similar uptake performances of SUVs and NCs, it is plausible that the developed NCs
fuse with the cell membrane due to the interaction of calcium ions with the membrane containing
negatively charged lipids, entering into the cells as nanovesicles [11]. A distinctive geometry, together
with peculiar internal interactions, makes NCs ideal as pharmaceutical carriers, which may provide
unparalleled protection for themolecular species in order to be carried harmlessly toward its destination.
Developed NCs are inexpensive, stable, monodisperse, highly safe, biocompatible, and cell-permeating
delivery systems. Moreover, they have high EE%, and suitable drug release properties for oral delivery,
but with possible uses in other routes of administration. NCs are characterised by a series of solid-lipid
bilayers; the components within the interior of this structure remain intact, even though the outer
layers of NCs may be exposed to harsh external environmental conditions or enzymes. This interior
structure of NCs is essentially free of water and resistant to penetration by oxygen, which leads to an
increased shelf-life of the formulation. NCs can be stored at room temperature or 4  C, and can be
lyophilised to a powder form. Thus, NCs can be used to formulate capsules, pills, tablets, granules,
suspensions or emulsions. Due to the ease of the internalisation process, this system could be exploited
by employing future in vivo experiments and could be of interest in various therapeutic options.
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